FDA approves a second Alzheimer's drug that can modestly slow disease

By Associated Press

Jul 03, 2024 4:14 pm

WASHINGTON, D.C. — US officials have approved another Alzheimer's drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

The Food and Drug Administration approved Eli Lilly's Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer's. It's only the second drug that's been convincingly shown to delay cognitive decline in patients, following last year's approval of a similar drug from Japanese drugmaker Eisai.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Machu Picchu security boosted after visitors spread human ashes

Xi, Lula meet in Brasilia to 'enhance ties'

UNAIDS chief says husband, Ugandan opposition figure Besigye, 'kidnapped'

SpaceX launches giant Starship rocket, but aborts attempt to catch booster with mechanical arms

HK court jails 45 democracy activists

Tens of thousands march in Maori rights protest

Chinese, Russian FMs discuss Korea tensions